Budipine, formerly known as BY-701 and Parkinsan, is a non-dopaminergic antiparkinsonian drug. The primary action of budipine is an indirect dopaminergic effect as shown by facilitation of dopamine (DA) release, inhibition of monoamine oxidase type B (MAO-B) and of DA (re) up-take and stimulation of aromatic L-amino acid decarboxylase (AADC), which in sum might be responsible for enhancing the endogenous dopaminergic activity. References: Reichmann H. Budipine in Parkinson's tremor. J Neurol Sci. 2006 Oct 25;248(1-2):53-5. Review. PubMed PMID: 16784759.

纯度：≥98%

CAS：63661-61-0